Evidence map›Paper›PMID 37093687›Full record

ArticleCancer genomics & proteomics

A Bioinformatics Assessment Indicating Better Outcomes With Breast Cancer Resident, Immunoglobulin CDR3-MMP2 Binding.

Suhaas R Mandala, Alexis J Thomson, Etienne C Gozlan, Dhruv N Patel, Andrea Chobrutskiy, Boris I Chobrutskiy, George Blanck

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer genomics & proteomics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 60% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Suhaas R MandalaDepartment of Molecular Medicine, Morsani College of Medicine, University of South Tampa, Tampa, FL, U.S.A.
Alexis J ThomsonDepartment of Molecular Medicine, Morsani College of Medicine, University of South Tampa, Tampa, FL, U.S.A.
Etienne C GozlanDepartment of Molecular Medicine, Morsani College of Medicine, University of South Tampa, Tampa, FL, U.S.A.
Dhruv N PatelDepartment of Molecular Medicine, Morsani College of Medicine, University of South Tampa, Tampa, FL, U.S.A.
Andrea ChobrutskiyDepartment of Pediatrics, Oregon Health and Science University Hospital, Portland, OR, U.S.A.
Boris I ChobrutskiyDepartment of Internal Medicine, Oregon Health and Science University Hospital, Portland, OR, U.S.A.
George BlanckDepartment of Molecular Medicine, Morsani College of Medicine, University of South Tampa, Tampa, FL, U.S.A.; gblanck@usf.edu.
University of South Florida · USOregon Health & Science University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimThe recombination of V, D, and J immunoglobulin (IG) gene segments leads to many variations in the amino acids (AAs) encoded at that site, the complementarity determining region-3 (CDR3). Thus, cancer patients may have varying degrees of CDR3 AA binding specificity for cancer proteases, for example, matrix metalloproteinase 2 (MMP2). MMP2 in breast cancer has been found to contribute to metastasis and is used as a marker for tumor staging. Thus, this report evaluated the tumor resident, patient specific IG CDR3 binding affinities to cancer proteases to test the hypothesis that greater binding affinities would be associated with a better outcome. MATERIALS AND

methodsUsing two independent bioinformatics tools, we evaluated the IG CDR3-MMP2 binding affinities throughout the cancer genome atlas breast cancer (TCGA-BRCA) dataset.

resultsResults indicated that the better the CDR3-MMP2 binding, the better the survival probability. An analogous evaluation for four other proteases, including calpain-1 and thermolysin, displayed no such associations with survival probabilities.

conclusionThis study is consistent with the possibility that patient IG-cancer protease interactions could impact outcomes and raises the question of whether therapeutic antibody targeting of MMP2 would reduce breast cancer mediated tissue destruction and breast cancer mortality rates.

Indexed as

Breast NeoplasmsComplementarity Determining RegionsComputational BiologyFemaleHumansMatrix Metalloproteinase 2Signal TransductionComplementarity Determining RegionsMatrix Metalloproteinase 2MMP2 protein, humanbreast cancerChemical complementarity bioinformaticsimmunoglobulin CDR3sMMP2

Identifiers

PMID37093687
PMCPMC10148069
OpenAlexW4366964329

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.